We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Nov 2023
  • Code : CMI5850
  • Pages :165
  • Formats :
      Excel and PDF
  • Industry : Clinical Diagnostic

The global PCOS diagnostic market size was valued at US$ 3.53 Bn in 2023 and is expected to reach US$ 4.96 Bn by 2030, grow at a compound annual growth rate (CAGR) of 5% from 2023 to 2030.

The growth of the PCOS diagnostic market is primarily driven by several key factors. Firstly, there is an increasing prevalence of PCOS, which is a hormonal disorder that primarily affects women of reproductive age. This rising prevalence contributes to the growing demand for an accurate and timely diagnosis of PCOS. Secondly, there is a growing awareness of PCOS among healthcare professionals and patients alike. This increased awareness leads to improved detection and diagnosis of the condition.

The development of new diagnostic tools and techniques plays a crucial role in driving market growth. These advancements enable healthcare providers to better identify and evaluate PCOS, leading to more effective management and treatment strategies. PCOS is a common condition, affecting 6-10% of women worldwide, and its cause is believed to be a combination of genetic and environmental factors.

PCOS diagnostic Market Regional Insights

  • North America: North America is a significant market for PCOS diagnostics. The region has a well-developed healthcare infrastructure, advanced diagnostic facilities, and a high prevalence of PCOS among women. Factors such as increased awareness, easy access to healthcare services, and favorable reimbursement policies contribute to the growth of the market in this region. Additionally, the presence of major diagnostic companies and ongoing research activities further drive market growth in North America. North America is the largest market for PCOS diagnostics, accounting for a share of over 40% in 2022.
  • Europe: Europe is another prominent market for PCOS diagnostics. The region has a strong emphasis on women's healthcare and advanced diagnostic capabilities. Countries like the U.K., Germany, and France have a high prevalence of PCOS. The market growth in Europe is driven by factors such as increasing awareness, government initiatives, and favorable healthcare policies supporting the early diagnosis and management of PCOS. Europe is the second-largest market for PCOS diagnostics, accounting for a share of over 25% in 2022.
  • Asia Pacific: The Asia Pacific region presents significant growth opportunities in the PCOS diagnostic market. Factors such as a large population, rising healthcare expenditure, and increasing awareness about women's health contribute to the market growth in this region. Countries like India and China have a high burden of PCOS, and the market is driven by the growing demand for diagnostic tests and advancements in healthcare infrastructure. Asia Pacific is the fastest-growing market for PCOS diagnostics, accounting for a share of over 20% in 2022.
  • Analyst View: The global PCOS diagnostic market is expected to grow significantly in the coming years. The increasing prevalence of PCOS among women globally is a major driver propelling the demand for effective diagnostic tests. Rising health awareness regarding PCOS and the availability of various diagnostic options are also contributing to the growth of this market. However, the market still faces certain restraints, such as a lack of awareness in developing nations. Additionally, the high cost of advanced diagnostic procedures is also hindering market growth to some extent. The market leaders are focusing on the development of rapid and accurate diagnostic tests to cater to the growing demand. North America dominates the global PCOS diagnostic market currently due to advanced healthcare facilities and rising healthcare expenditures. Asia Pacific is expected to be the fastest-growing regional market, attributed to improving healthcare infrastructure and increasing disposable incomes. Players are investing in research activities to develop novel diagnostic solutions for the early and quick diagnosis of PCOS. Adoption of artificial intelligence and machine learning technologies also presents lucrative growth opportunities in this domain. Collaboration with doctors and scientific research organizations can help market players gain insights for product innovations. To conclude, the global PCOS Diagnostic market has immense growth potential given the rising efforts taken for awareness campaigns and new product launches by the key industry stakeholders in this field.

Figure 1. Global PCOS diagnostic Market Share (%), by Region, 2023


To learn more about this report, request a free sample copy

PCOS diagnostic Market Drivers:

  • Increasing Prevalence of PCOS: PCOS is a common hormonal disorder, affecting a significant number of women worldwide. The increasing prevalence of PCOS is one of the primary drivers of the global PCOS diagnostic market. According to various studies, the prevalence of PCOS ranges from 5% to 20% globally.
  • Growing Awareness and Early Diagnosis: There is a growing awareness among healthcare professionals and patients about PCOS and its potential health risks. Early diagnosis of PCOS is crucial for effective management and prevention of associated complications, such as infertility, metabolic disorders, and cardiovascular This awareness drives the demand for PCOS diagnostic tests.
  • Technological Advancements in Diagnostics: Advances in diagnostic technologies, such as ultrasound, hormonal assays, and genetic testing, have improved the accuracy and efficiency of PCOS diagnosis. These technological advancements enable healthcare providers to diagnose PCOS more effectively and contribute to the growth of the PCOS diagnostic market.
  • Rising Healthcare Expenditure: Increasing healthcare expenditure, particularly in developing countries, supports the expansion of the PCOS diagnostic market. As healthcare infrastructure improves and access to healthcare services expands, more individuals have the opportunity to undergo PCOS diagnostic tests, driving market growth.

PCOS diagnostic Market Opportunities:

  • Increasing Demand for Point-of-Care Testing: Point-of-care testing (POCT) offers the advantage of providing rapid and convenient diagnostic results at the patient's bedside or in a primary care setting. As the demand for early and efficient diagnosis of PCOS grows, there is an opportunity for the development and commercialization of POCT devices specifically designed for PCOS diagnostics. These devices can enhance accessibility, reduce turnaround time, and improve patient outcomes.
  • Integration of Artificial Intelligence (AI) and Machine Learning (ML): AI and ML technologies have the potential to revolutionize PCOS diagnostics by improving the accuracy and efficiency of diagnosis and prognosis. These technologies can analyze large datasets, identify patterns, and provide personalized recommendations. By integrating AI and Machine Learning algorithms into PCOS diagnostic tools, there is an opportunity to enhance diagnostic accuracy, optimize treatment plans, and enable personalized medicine approaches.
  • Expansion into Emerging Markets: The PCOS diagnostic market has significant growth potential in emerging markets, including Asia-Pacific, Latin America, and the Middle East. These regions have large populations, increasing healthcare expenditures, and a rising awareness of women's health issues. Companies that expand their presence in these markets can tap into the growing demand for PCOS diagnostics and establish a strong foothold for long-term growth.
  • Development of Non-Invasive Diagnostic Methods: Currently, PCOS diagnosis relies on a combination of symptoms assessment, physical examination, and laboratory tests. However, there is an opportunity to develop non-invasive diagnostic methods that are less burdensome for patients. For example, the use of imaging techniques such as transvaginal ultrasound or new biomarkers in blood or urine samples may provide less invasive options for PCOS diagnosis, leading to improved patient experience and increased adoption of diagnostic tests.

PCOS diagnostic Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 3.53 Bn
Historical Data for: 2018 to 2022 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 5% 2030 Value Projection: US$ 4.96 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa 
Segments covered:
  • By Type of Diagnostic Test: Hormone Test, Imaging Tests, Blood Tests, Pelvic Examination, Genetic Testing, Other Tests
  • By End-User: Hospitals & Clinics, Fertility Clinics, Homecare Settings, Diagnostic Laboratories
Companies covered:

F. Hoffmann-La Roche Ltd, Abbott, Quest Diagnostics, Thermo Fisher Scientific, Inc., Siemens Healthineers, Bio-Rad Laboratories, Hologic, Inc., Vitrolife, Myriad Genetics, Inc., Ansh Labs, Diagnostica Stago Inc., Beckman Coulter, Inc., Randox Laboratories Ltd., GE Healthcare, PrivaPath Diagnostics, Laboratory Corporation of America Holdings, SRL Diagnostics

Growth Drivers:
  • Increasing Prevalence of PCOS
  • Growing Awareness and Early Diagnosis
  • Technological Advancements in Diagnostics
  • Rising Healthcare Expenditure
Restraints & Challenges:
  • Lack of Standardized Diagnostic Criteria
  • Limited Awareness and under diagnosis
  • Cost and Affordability

PCOS diagnostic Market Trends:

  • Shift towards Multimodal Diagnostic Approaches: There is a growing trend towards utilizing a combination of diagnostic modalities to improve the accuracy of PCOS diagnosis. Rather than relying solely on symptom assessment or a single laboratory test, healthcare providers are increasingly using a multimodal approach that combines clinical evaluation, imaging techniques (such as ultrasound), and hormone profiling to achieve more comprehensive and accurate diagnostic results.
  • Focus on Early Detection and Intervention: Early detection of PCOS is gaining more attention as healthcare providers recognize the importance of early intervention to prevent long-term complications. Timely diagnosis allows for appropriate management strategies, lifestyle interventions, and targeted therapies to be implemented, which can potentially mitigate the development and progression of PCOS-related complications.
  • Growing Integration of Molecular Diagnostics: Molecular diagnostic techniques, including genetic testing and gene expression profiling, are being explored for their potential in PCOS diagnosis. These approaches aim to identify specific genetic variations or gene expression patterns associated with PCOS, providing insights into the underlying pathophysiology and aiding in personalized treatment decisions.
  • Rising Demand for Home-based Testing: With the increasing emphasis on convenience and patient-centric care, there is a trend towards home-based PCOS testing. Home testing kits that enable individuals to collect samples (such as blood or urine) at home and send them to a laboratory for analysis are gaining popularity. These kits offer privacy, convenience, and ease of use, allowing individuals to monitor their PCOS-related parameters in the comfort of their homes.

PCOS diagnostic Market Restraints:

  • Lack of Standardized Diagnostic Criteria: PCOS diagnosis is currently based on a combination of clinical, biochemical, and imaging criteria. However, there is still ongoing debate and a lack of consensus on the specific diagnostic criteria. The lack of standardized diagnostic criteria can lead to variability in diagnosis and potentially hinder accurate assessment and comparability of diagnostic results.
  • Limited Awareness and Under diagnosis: Despite the increasing prevalence of PCOS, there is still a lack of awareness and understanding of the condition among healthcare providers and the general population. This can result in under diagnosis or misdiagnosis, delaying appropriate management, and posing potential risks associated with untreated or poorly managed
  • Cost and Affordability: The cost of PCOS diagnostic tests and procedures can be a significant restraint, especially in resource-constrained settings. Some diagnostic methods, such as hormonal assays and imaging techniques, may require specialized equipment and expertise, which can drive up costs. The affordability of PCOS diagnostic tests can be a barrier for individuals seeking a timely and accurate diagnosis, particularly in regions with limited access to healthcare resources.

Recent Developments

New product launches

  • In October 2022, Veera Health, one of the largest digital therapeutic platforms for managing polycystic ovary syndrome (PCOS), recently launched a comprehensive test for diagnosing PCOS. The diagnostic packages are currently available in 24 Indian cities including Agra, Allahabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Faridabad, Ghaziabad, Gurgaon, Howrah WB, Hyderabad, Jaipur, Kanpur, Kolkata, Lucknow, Meerut, Mumbai, New Delhi, Noida, Patna, Pune, Ranchi, Surat, and Varanasi.
  • In November 2021, Allara Health Inc., a provider of diagnostic test kits, announced the launch of its diagnostic test for polycystic ovary syndrome (PCOS), to overcome the huge demand for PCOS diagnostic
  • In 2021, Arogya Meditech, a biotechnology company, launched "PCOScan," a diagnostic test designed specifically for PCOS. PCOScan is a comprehensive blood-based test that measures multiple hormonal parameters and provides an assessment of PCOS risk. It aims to provide an accurate and convenient diagnostic tool for healthcare providers and patients.
  • In 2020, Hoffmann-La Roche Ltd., a pharmaceutical company, launched the Elecsys Anti-Müllerian Hormone (AMH) immunoassay, a test that measures AMH levels in blood samples. AMH is a hormone that plays a role in ovarian function and can be used as a marker for PCOS diagnosis and assessment of ovarian reserve.

Acquisition and partnerships

  • On July 6, 2023, Proov, a company that developed an at-home PdG test that measures the presence of progesterone metabolite PdG in urine, announced a collaboration with Quest Diagnostics, a company that provides diagnostic test kits for PCOS to access the Proov Confirm PdG home collection kit for assessing fertility through questhealth.com.
  • On June 27, 2023, Thriva Ltd, a company offering health tests, announced partnership with Superdrug, a company that provides online health test kits to help people spot the warning signs of disease and positively change their behaviors.
  • Thermo Fisher Scientific Acquires Mesa Biotech (February 2021): Thermo Fisher Scientific, a leading life sciences company, acquired Mesa Biotech, a molecular diagnostic company. This acquisition aimed to strengthen Thermo Fisher's position in the point-of-care molecular diagnostics market, including the PCOS diagnostic segment.
  • Quest Diagnostics and Let's Get Checked Partnership (2021): Quest Diagnostics, one of the largest diagnostic testing providers, partnered with Let's Get Checked, a direct-to-consumer testing company. This partnership allowed Quest Diagnostics to expand its reach in the consumer market and offer at-home PCOS diagnostic testing options through Let's Get Checked's platform.

Figure 2. Global PCOS diagnostic Market Share (%), by Type, 2023


To learn more about this report, request a free sample copy

Top companies in PCOS diagnostic Market

  • F. Hoffmann-La Roche Ltd
  • Abbott
  • Quest Diagnostics
  • Thermo Fisher Scientific, Inc.
  • Siemens Healthineers
  • Bio-Rad Laboratories
  • Hologic, Inc.
  • Vitrolife
  • Myriad Genetics, Inc.
  • Ansh Labs
  • Diagnostica Stago Inc.
  • Beckman Coulter, Inc.
  • Randox Laboratories Ltd.
  • GE Healthcare
  • PrivaPath Diagnostics
  • Laboratory Corporation of America Holdings
  • SRL Diagnostics

*Definition: PCOS diagnostic refers to the process of identifying and evaluating Polycystic Ovary Syndrome (PCOS), a hormonal disorder commonly affecting women of reproductive age. It involves a series of tests and assessments to diagnose the condition, including hormone level measurements, ultrasound imaging of the ovaries, and analysis of clinical symptoms.

Frequently Asked Questions

The Factor such as Lack of standardized diagnostic criteria, limited awareness and under diagnosis, and cost and affordability of diagnostic tests can hamper the growth of market

The factor such as increasing prevalence of PCOS, rising awareness of PCOS among healthcare professionals and patients, and development of new diagnostic tools and techniques expected to drive the market growth over the forecast period

Blood tests is leading diagnostic test in market

F.Hoffmann-La Roche Ltd, Abbott, Quest Diagnostics, Thermo Fisher Scientific, Inc., Siemens Healthineers, Bio-Rad Laboratories, Hologic, Inc., Vitrolife, Myriad Genetics, Inc., Ansh Labs, Diagnostica Stago Inc., Beckman Coulter, Inc., Randox Laboratories Ltd., GE Healthcare, PrivaPath Diagnostics, Laboratory Corporation of America Holdings, SRL Diagnostics

North America is expected to lead the market, followed by Europe and the Asia Pacific region.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Reliability and Reputation


Reliability and Reputation


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo